Thyroid hormone receptor alpha and beta (TRα and TRβ)

Thyroid hormone receptor alpha and beta are members of the nuclear hormone receptor superfamily that act as hormone-activated transcription factors, modulating gene expression in response to thyroid hormones (T3 and T4)[1][5][2]. Encoded by the THRA (alpha) and THRB (beta) genes, they exist in multiple isoforms generated by alternative splicing, with distinct but sometimes overlapping expression and physiological roles in different tissues and stages of development[1][3][5]. TRα is prevalent in the brain, heart, skeletal muscle, and adipose tissue, while TRβ dominates in liver, heart, and pituitary, crucially regulating cholesterol metabolism, TSH feedback, and energy homeostasis[5][8]. Dysfunction or mutation in these receptors is associated with syndromes of thyroid hormone resistance, altered metabolism, developmental defects, and increased risk of several diseases, including cancer and neurodevelopmental disorders[2][8][3][4]. Thyroid hormone receptors are well-established targets for endogenous thyroid hormones (T3, T4) and synthetic analogs used in the treatment of hypothyroidism and other thyroid-related disorders, as well as for experimental selective modulators aimed at metabolic and cardiovascular disease[5][2][8]. Their ligand-binding, DNA-binding, and transactivation domains allow direct gene regulation, with complex tissue- and isoform-specific actions underlying their broad physiological importance[1][5].

Other names

nuclear receptor subfamily 1, group A, member 1 (TRα/NR1A1)nuclear receptor subfamily 1, group A, member 2 (TRβ/NR1A2)c-erbA

Agonists (e.g., thyroid hormones or synthetic analogs) bind and activate the receptor to induce gene transcription Antagonists or mutations can block or dysregulate receptor-mediated transcriptional activation/repression